Haemonetics Corporation (HAE) - Fiscal Year 2025 10-K Summary
Business Context and Reporting Period
Company: Haemonetics Corporation
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended March 29, 2025 (52 weeks)
Business Overview: Haemonetics is a global medical technology company operating in three segments: Plasma (source plasma collection), Blood Center (blood collection and processing), and Hospital (Interventional Technologies and Blood Management Technologies). The company focuses on improving healthcare quality and efficiency through innovative solutions for plasma collection, blood management, and hospital procedures.
Key Financial Metrics
| Metric (in thousands, except per share) | Fiscal 2025 | Fiscal 2024 | Change |
|---|---|---|---|
| Net Revenues | $1,360,824 | $1,309,055 | +4.0% |
| Gross Profit | $748,958 | $691,548 | +8.3% |
| Gross Margin | 55.0% | 52.8% | +220 bps |
| Operating Income | $221,817 | $164,883 | +34.5% |
| Operating Margin | 16.3% | 12.6% | +370 bps |
| Net Income | $167,679 | $117,558 | +42.6% |
| Diluted EPS | $3.31 | $2.29 | +44.5% |
| Cash and Cash Equivalents | $306,763 | $178,800 | N/A |
| Net Debt Position | ($918,025) | ($628,993) | N/A |
| Operating Cash Flow | $181,725 | $181,751 | Flat |
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 4.0% (4.3% constant currency). Growth was driven by the Hospital segment (+23.7%), primarily due to recent acquisitions (OpSens and Attune Medical) and volume/price benefits. This was partially offset by declines in Plasma (-6.0%) and Blood Center (-7.8%).
- Profitability Expansion: Operating income surged 34.5% due to operating leverage, a $23.0 million benefit from the remeasurement of contingent consideration, decreased performance-based compensation, and a gain on the sale of a manufacturing facility. These were partially offset by increased amortization of acquired intangible assets ($48.3 million vs. $32.0 million) and acquisition integration costs.
- Segment Performance:
- Plasma: Revenue declined due to lower sales volumes in North America related to the customer transition of CSL Plasma. A one-time $10.6 million shortfall payment was recorded in Q4.
- Blood Center: Revenue declined primarily due to the divestiture of the Whole Blood product line in Q4 2025.
- Hospital: Revenue grew significantly, driven by Interventional Technologies (Vascular Closure, Sensor-Guided, Esophageal Protection) and Blood Management Technologies.
- Divestiture: Completed the sale of the Whole Blood product line to GVS, S.p.A. for total cash consideration of up to $65.8 million ($43.3 million upfront).
- Acquisitions: Integrated Attune Medical (Esophageal Protection) and OpSens (Sensor-Guided Technologies), which contributed to Hospital segment growth.
Guidance, Outlook, and Risks
- Strategic Initiatives: In May 2025, the Board approved a "Market and Regional Alignment" initiative expected to incur approximately $20 million in restructuring charges (mostly severance and exit costs) through fiscal 2027, targeting $30 million in annualized savings.
- Capital Allocation: The Board approved a new $500 million share repurchase authorization in April 2025. The company fully funded the previous $300 million authorization by March 29, 2025.
- Debt Profile: The company has $1.0 billion in convertible senior notes ($300 million due 2026, $700 million due 2029) and a $250 million term loan. The 2026 Notes mature in March 2026; the company plans to repay using cash on hand and revolver borrowings.
- Key Risks:
- Customer Concentration: The ten largest customers accounted for 42% of net revenues in fiscal 2025. The Plasma segment relies heavily on a limited number of biopharmaceutical customers.
- Regulatory Environment: Compliance with FDA, EU MDR, and IVDR regulations is critical. Changes in regulations or failure to obtain approvals could impact revenue.
- Supply Chain: Exposure to raw material costs (plastics), geopolitical tensions, and reliance on sole-source suppliers.
- Competition: Intense competition in vascular closure, sensor-guided technologies, and plasma collection from companies like Terumo BCT, Fresenius, and Abbott.
Investor Verification Checklist
- CSL Plasma Transition: Verify the impact of the CSL Plasma contract expiration (December 2025) on future Plasma segment revenue, as no North America disposables sales are expected in fiscal 2026.
- 2026 Notes Maturity: Confirm the company's liquidity plan for the $300 million convertible note maturity in March 2026, including reliance on the revolving credit facility.
- Restructuring Execution: Monitor the execution of the new "Market and Regional Alignment" initiative and the realization of the projected $30 million in annualized savings.
- Acquisition Integration: Assess the integration progress and revenue contribution of Attune Medical and OpSens to the Hospital segment.
- Whole Blood Divestiture: Review the transition services agreement (TSA) and contract manufacturing agreement (CMA) with GVS to understand any residual revenue or cost impacts from the divested business.